Browse EX-10 agreements

**LATIGO BIOTHERAPEUTICS, INC. **

**NON-EMPLOYEE DIRECTOR COMPENSATION POLICY **

**ADOPTED: JUNE 17, 2026 **

Each member of the Board of Directors (the “Board”) of Latigo Biotherapeutics, Inc. (the “Company”) who is not also serving as an employee of or consultant to the Company or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”) for his or her Board service upon and following the date of the underwriting agreement between the Company and the underwriters managing the initial public offering of the Company’s common stock (the “Common Stock”), pursuant to which the Common Stock is priced in such initial public offering (such date, the “Effective Date”).

This Policy will be effective as of the Effective Date and may be amended at any time in the sole discretion of the Board or the Compensation Committee of the Board (the “Compensation Committee”).

…

**LATIGO BIOTHERAPEUTICS, INC. **

**2026 EMPLOYEE STOCK PURCHASE PLAN **

**ADOPTED BY THE BOARD OF DIRECTORS: JUNE 17, 2026 **

**APPROVED BY THE STOCKHOLDERS: JULY 28, 2026 **

**1. GENERAL; PURPOSE. **

(a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan. In addition, the Plan permits the Company to grant a series of Purchase Rights to Eligible Employees that do not meet the requirements of an Employee Stock Purchase Plan.

…

**LATIGO BIOTHERAPEUTICS, INC. **

**2026 EQUITY INCENTIVE PLAN **

**ADOPTED BY THE BOARD OF DIRECTORS: JUNE 17, 2026 **

**APPROVED BY THE STOCKHOLDERS: JULY 28, 2026 **

1.	GENERAL.

(a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) the Prior Plan’s Available Reserve plus any Returning Shares will become available for issuance pursuant to Awards granted under this Plan; and (iii) all outstanding awards granted under the Prior Plan will remain subject to the terms of the Prior Plan (except to the extent such outstanding Awards result in Returning Shares that become available for issuance pursuant to Awards granted under this Plan). All Awards granted under this Plan will be subject to the terms of this Plan.

…

**BLOSSOMHILL THERAPEUTICS, INC. **

**EXECUTIVE EMPLOYMENT AGREEMENT **

**for **

**Yishan Peter Li, Ph.D., M.B.A. **

This Executive Employment Agreement (this “Agreement”), is made and entered into on July 31, 2026, by and between Yishan Peter Li, Ph.D., M.B.A. (“Executive”) and BlossomHill Therapeutics, Inc. (the “Company”). This Agreement is contingent and shall only be effective immediately prior to such time as the U.S. Securities and Exchange Commission declares the Company’s registration statement on Form S-1 for its initial public offering effective (such date, the “Effective Date”).

WHEREAS, the Company and Executive desire to enter into an agreement of employment on the terms set forth herein to amend and restate the terms of the Executive’s continued employment with the Company.

WHEREAS, as of the Effective Date, this Agreement shall supersede and replace the Employment Agreement between the Executive and the Company, dated March 3, 2021 (the “Prior Agreement”).

…

**BLOSSOMHILL THERAPEUTICS, INC. **

**NON-EMPLOYEE DIRECTOR COMPENSATION POLICY **

**ADOPTED: JUNE 25, 2026 **

Each member of the Board of Directors (the “Board”) of BlossomHill Therapeutics, Inc. (the “Company”) who is not also serving as an employee of or consultant to the Company or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”) for his or her Board service upon and following the date of the underwriting agreement between the Company and the underwriters managing the initial public offering of the Company’s common stock (the “***Common ***Stock”), pursuant to which the Common Stock is priced in such initial public offering (such date, the “Effective Date”).

This Policy will be effective as of the Effective Date and may be amended at any time in the sole discretion of the Board or the Compensation Committee of the Board (the “Compensation Committee”).

…

***INDEMNIFICATION AGREEMENT ***

This Indemnification Agreement is dated as of _________, 2026 (this “Agreement”) and is between BlossomHill Therapeutics, Inc., a Delaware corporation (the “Company”), and [Name] (“Indemnitee”).

Background

The Company believes that in order to attract and retain highly competent persons to serve as directors or in other capacities, including as officers, it must provide such persons with adequate protection through indemnification against the risks of claims and actions against them arising out of their services to and activities on behalf of the Company.

The Company desires and has requested Indemnitee to serve as a director and/or officer of the Company and, in order to induce the Indemnitee to serve in such capacity, the Company is willing to grant the Indemnitee the indemnification provided for herein. Indemnitee is willing to so serve on the basis that such indemnification be provided.

…

**CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. **

**BLOSSOMHILL THERAPEUTICS, INC. **

**EXECUTIVE EMPLOYMENT AGREEMENT **

**for **

**Geoffrey Oxnard, M.D. **

This Executive Employment Agreement (this “Agreement”), is made and entered into on July 31, 2026, by and between Geoffrey Oxnard, M.D. (“Executive”) and BlossomHill Therapeutics, Inc. (the “Company”). This Agreement is contingent and shall only be effective immediately prior to such time as the U.S. Securities and Exchange Commission declares the Company’s registration statement on Form S-1 for its initial public offering effective (such date, the “Effective Date”).

WHEREAS, the Company and Executive desire to enter into an agreement of employment on the terms set forth herein to amend and restate the terms of the Executive’s continued employment with the Company.

…

**BLOSSOMHILL THERAPEUTICS, INC. **

**EXECUTIVE EMPLOYMENT AGREEMENT **

**for **

**Jingrong Jean Cui, Ph.D. **

This Executive Employment Agreement (this “Agreement”), is made and entered into on July 31, 2026, by and between Jingrong Jean Cui, Ph.D. (“Executive”) and BlossomHill Therapeutics, Inc. (the “Company”). This Agreement is contingent and shall only be effective immediately prior to such time as the U.S. Securities and Exchange Commission declares the Company’s registration statement on Form S-1 for its initial public offering effective (such date, the “Effective Date”).

WHEREAS, the Company and Executive desire to enter into an agreement of employment on the terms set forth herein to amend and restate the terms of the Executive’s continued employment with the Company.

WHEREAS, as of the Effective Date, this Agreement shall supersede and replace the Employment Agreement between the Executive and the Company, dated March 3, 2021 (the “Prior Agreement”).

…

**BLOSSOMHILL THERAPEUTICS, INC. **

**EXECUTIVE EMPLOYMENT AGREEMENT **

**for **

**Vincent Liptak, J.D., Ph.D., M.B.A. **

This Executive Employment Agreement (this “Agreement”), is made and entered into on July 31, 2026, by and between Vincent Liptak, J.D., Ph.D., M.B.A. (“Executive”) and BlossomHill Therapeutics, Inc. (the “Company”). This Agreement is contingent and shall only be effective immediately prior to such time as the U.S. Securities and Exchange Commission declares the Company’s registration statement on Form S-1 for its initial public offering effective (such date, the “Effective Date”).

WHEREAS, the Company and Executive desire to enter into an agreement of employment on the terms set forth herein to amend and restate the terms of the Executive’s continued employment with the Company.

WHEREAS, as of the Effective Date, this Agreement shall supersede and replace the Offer Letter between the Executive and the Company, dated March 6, 2023 (the “Prior Agreement”).

…

**BLOSSOMHILL THERAPEUTICS, INC. **

**2026 EMPLOYEE STOCK PURCHASE PLAN **

**ADOPTED BY THE BOARD OF DIRECTORS: JUNE 25, 2026 **

**APPROVED BY THE STOCKHOLDERS: JULY 30, 2026 **

1.	**GENERAL; PURPOSE. **

(a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan. In addition, the Plan permits the Company to grant a series of Purchase Rights to Eligible Employees that do not meet the requirements of an Employee Stock Purchase Plan.

…

**BLOSSOMHILL THERAPEUTICS, INC. **

**2026 EQUITY INCENTIVE PLAN **

**ADOPTED BY THE BOARD OF DIRECTORS: JUNE 25, 2026 **

**APPROVED BY THE STOCKHOLDERS: JULY 30, 2026 **

1.	**GENERAL. **

(a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) the Prior Plan’s Available Reserve plus any Returning Shares will become available for issuance pursuant to Awards granted under this Plan; and (iii) all outstanding awards granted under the Prior Plan will remain subject to the terms of the Prior Plan (except to the extent such outstanding Awards result in Returning Shares that become available for issuance pursuant to Awards granted under this Plan). All Awards granted under this Plan will be subject to the terms of this Plan.

…

**BLOSSOMHILL THERAPEUTICS, INC. **

**EXECUTIVE EMPLOYMENT AGREEMENT **

**for **

**Jason Keyes, M.B.A. **

This Executive Employment Agreement (this “Agreement”), is made and entered into on July 31, 2026, by and between Jason Keyes, M.B.A. (“Executive”) and BlossomHill Therapeutics, Inc. (the “Company”). This Agreement is contingent and shall only be effective immediately prior to such time as the U.S. Securities and Exchange Commission declares the Company’s registration statement on Form S-1 for its initial public offering effective (such date, the “Effective Date”).

WHEREAS, the Company and Executive desire to enter into an agreement of employment on the terms set forth herein to amend and restate the terms of the Executive’s continued employment with the Company.

WHEREAS, as of the Effective Date, this Agreement shall supersede and replace the Offer Letter between the Executive and the Company, dated March 27, 2025 (the “Prior Agreement”).

…